

# Benjamin Caplin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2176328/publications.pdf>

Version: 2024-02-01

64  
papers

3,977  
citations

236612

25  
h-index

155451

55  
g-index

67  
all docs

67  
docs citations

67  
times ranked

6951  
citing authors

#	ARTICLE	IF	CITATIONS
1	Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. <i>Lancet, The</i> , 2022, 399, 665-676.	6.3	280
2	Severity of COVID-19 after Vaccination among Hemodialysis Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 843-850.	2.2	34
3	Outcome and effect of vaccination in SARS-CoV-2 Omicron infection in hemodialysis patients: a cohort study. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1944-1950.	0.4	14
4	“Epigenome-wide methylation profile of chronic kidney disease-derived arterial DNA uncovers novel pathways in disease-associated cardiovascular pathology.” <i>Epigenetics</i> , 2021, 16, 718-728.	1.3	10
5	Feasibility of evaluation of the natural history of kidney disease in the general population using electronic healthcare records. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 1603-1609.	1.4	1
6	CKD and CKDu in northern Peru: a cross-sectional analysis under the DEGREE protocol. <i>BMC Nephrology</i> , 2021, 22, 37.	0.8	2
7	Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. <i>Lancet, The</i> , 2021, 397, 605-612.	6.3	234
8	Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. <i>Lancet, The</i> , 2021, 397, 1637-1645.	6.3	1,374
9	Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. <i>Lancet, The</i> , 2021, 397, 2049-2059.	6.3	391
10	Risk of COVID-19 Disease, Dialysis Unit Attributes, and Infection Control Strategy among London In-Center Hemodialysis Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 1237-1246.	2.2	30
11	Identifying prognostic risk factors for poor outcome following COVID-19 disease among in-centre haemodialysis patients: role of inflammation and frailty. <i>Journal of Nephrology</i> , 2021, 34, 315-323.	0.9	21
12	Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. <i>Lancet Respiratory Medicine, the</i> , 2021, 9, 1419-1426.	5.2	123
13	Lupus Nephritis and Chronic Kidney Disease. <i>Journal of Rheumatology</i> , 2020, 47, 1303-1304.	1.0	8
14	Prevalence and risk factors for chronic kidney disease of unknown cause in Malawi: a cross-sectional analysis in a rural and urban population. <i>BMC Nephrology</i> , 2020, 21, 387.	0.8	8
15	HEROIC: a 5-year observational cohort study aimed at identifying novel factors that drive diabetic kidney disease: rationale and study protocol. <i>BMJ Open</i> , 2020, 10, e033923.	0.8	1
16	FP377FEASIBILITY OF EVALUATION OF THE NATURAL HISTORY OF KIDNEY DISEASE USING PRIMARY CARE ELECTRONIC HEALTHCARE RECORDS. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, .	0.4	0
17	Identification of young adults at risk of an accelerated loss of kidney function in an area affected by Mesoamerican nephropathy. <i>BMC Nephrology</i> , 2019, 20, 21.	0.8	8
18	Prevalence and risk factors for impaired kidney function in the district of Anuradhapura, Sri Lanka: a cross-sectional population-representative survey in those at risk of chronic kidney disease of unknown aetiology. <i>BMC Public Health</i> , 2019, 19, 763.	1.2	31

#	ARTICLE	IF	CITATIONS
19	CKD of Unknown Cause: A Global Epidemic?. <i>Kidney International Reports</i> , 2019, 4, 367-369.	0.4	18
20	Prevalence of and risk factors for chronic kidney disease of unknown aetiology in India: secondary data analysis of three population-based cross-sectional studies. <i>BMJ Open</i> , 2019, 9, e023353.	0.8	27
21	Let's take the heat out of the CKDu debate: more evidence is needed. <i>Occupational and Environmental Medicine</i> , 2019, 76, 357-359.	1.3	33
22	Chronic kidney disease of undetermined aetiology: tens of thousands of premature deaths, yet too much remains unknown. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1839-1841.	0.4	5
23	Rationale and population-based prospective cohort protocol for the disadvantaged populations at risk of decline in eGFR (CO-DEGREE). <i>BMJ Open</i> , 2019, 9, e031169.	0.8	20
24	Epidemiology, molecular, and genetic methodologies to evaluate causes of CKDu around the world: report of the Working Group from the ISN International Consortium of Collaborators on CKDu. <i>Kidney International</i> , 2019, 96, 1254-1260.	2.6	16
25	Environmental exposures in young adults with declining kidney function in a population at risk of Mesoamerican nephropathy. <i>Occupational and Environmental Medicine</i> , 2019, 76, 920-926.	1.3	27
26	The International Society of Nephrology's International Consortium of Collaborators on Chronic Kidney Disease of Unknown Etiology: report of the working group on approaches to population-level detection strategies and recommendations for a minimum dataset. <i>Kidney International</i> , 2019, 95, 4-10.	2.6	45
27	The use of sirolimus in patients with recurrent cytomegalovirus infection after kidney transplantation: A retrospective case series analysis. <i>Saudi Journal of Kidney Diseases and Transplantation: an Official Publication of the Saudi Center for Organ Transplantation, Saudi Arabia</i> , 2019, 30, 606.	0.4	9
28	Different rates of progression and mortality in patients with chronic kidney disease at outpatient nephrology clinics across Europe. <i>Kidney International</i> , 2018, 93, 1432-1441.	2.6	36
29	FP366 OUTCOMES OF PEOPLE WITH CHRONIC KIDNEY DISEASE STAGES 3-5 MANAGED IN PRIMARY CARE IN THE UK - FINDINGS FROM THE NATIONAL CKD AUDIT. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i155-i155.	0.4	0
30	The National CKD Audit: a primary care condition that deserves more attention. <i>British Journal of General Practice</i> , 2018, 68, 356-357.	0.7	5
31	Chronic kidney disease and cause-specific hospitalisation: a matched cohort study using primary and secondary care patient data. <i>British Journal of General Practice</i> , 2018, 68, e512-e523.	0.7	21
32	How do primary care doctors in England and Wales code and manage people with chronic kidney disease? Results from the National Chronic Kidney Disease Audit. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 1373-1379.	0.4	34
33	What do epidemiological studies tell us about chronic kidney disease of undetermined cause in Meso-America? A systematic review and meta-analysis. <i>CKJ: Clinical Kidney Journal</i> , 2018, 11, 496-506.	1.4	73
34	Decline in Kidney Function among Apparently Healthy Young Adults at Risk of Mesoamerican Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 2200-2212.	3.0	60
35	Galactosylation of IgA1 Is Associated with Common Variation in C1GALT1. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 2158-2166.	3.0	93
36	Rationale, description and baseline findings of a community-based prospective cohort study of kidney function amongst the young rural population of Northwest Nicaragua. <i>BMC Nephrology</i> , 2017, 18, 16.	0.8	18

#	ARTICLE	IF	CITATIONS
37	Accounting for overdispersion when determining primary care outliers for the identification of chronic kidney disease: learning from the National Chronic Kidney Disease Audit. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, ii151-ii158.	0.4	5
38	Urinary biomarkers of tubular injury in chronic kidney disease. <i>Kidney International</i> , 2017, 91, 21-23.	2.6	11
39	International Collaboration for the Epidemiology of eGFR in Low and Middle Income Populations - Rationale and core protocol for the Disadvantaged Populations eGFR Epidemiology Study (DEGREE). <i>BMC Nephrology</i> , 2017, 18, 1.	0.8	145
40	Association of Serum Calprotectin (S100A8/A9) Level With Disease Relapse in Proteinase 3 Antineutrophil Cytoplasmic Antibody Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2017, 69, 185-193.	2.9	45
41	Chronic kidney disease-associated cardiovascular disease: scope and limitations of animal models. <i>Cardiovascular Endocrinology</i> , 2017, 6, 120-127.	0.8	5
42	MP313 IDENTIFYING OUTLYING PRACTICES IN PREVALENCE OF CKD IN PRIMARY CARE. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, i443-i443.	0.4	0
43	Infection Rates Following Buttonhole Cannulation in Hemodialysis Patients. <i>Therapeutic Apheresis and Dialysis</i> , 2016, 20, 476-482.	0.4	22
44	CME Renal medicine (100621): self-assessment questionnaire. <i>Clinical Medicine</i> , 2015, 15, 589-590.	0.8	0
45	SP847 THE USE OF mTORi IN PATIENTS WITH RECURRENT CMV INFECTION AFTER KIDNEY TRANSPLANTATION. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, iii656-iii657.	0.4	0
46	Peritoneal Protein Clearance Rather than Faster Transport Status Determines Outcomes in Peritoneal Dialysis Patients. <i>Peritoneal Dialysis International</i> , 2015, 35, 216-221.	1.1	39
47	Dimethylarginine Dimethylaminohydrolase 2 Regulates Nitric Oxide Synthesis and Hemodynamics and Determines Outcome in Polymicrobial Sepsis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 1382-1392.	1.1	47
48	Reduced Renal Methylarginine Metabolism Protects against Progressive Kidney Damage. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 3045-3059.	3.0	31
49	Long-term outcome of anti-neutrophil cytoplasm antibody-associated glomerulonephritis: evaluation of the international histological classification and other prognostic factors. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1185-1192.	0.4	94
50	Does Online Haemodiafiltration Reduce Intra-Dialytic Patient Symptoms?. <i>Nephron Clinical Practice</i> , 2014, 124, 184-190.	2.3	19
51	Assessment of the Renal Patient. , 2014, , 1-17.		0
52	Chronic Kidney Disease: Cardiovascular Complications. , 2014, , 589-601.		0
53	Early changes in scores of chronic damage on transplant kidney protocol biopsies reflect donor characteristics, but not future graft function. <i>Clinical Transplantation</i> , 2013, 27, E669-78.	0.8	5
54	New Observational Data Demonstrate that Mortality Is Lower in Patients Receiving More Frequent Dialysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2012, 23, 770-773.	3.0	3

#	ARTICLE	IF	CITATIONS
55	Endogenous Nitric Oxide Synthase Inhibitors in the Biology of Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2012, 32, 1343-1353.	1.1	82
56	Alanine-Glyoxylate Aminotransferase-2 Metabolizes Endogenous Methylarginines, Regulates NO, and Controls Blood Pressure. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2012, 32, 2892-2900.	1.1	70
57	Patients' perspective of haemodialysis-associated symptoms. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 2656-2663.	0.4	163
58	RENAL DISEASE IS ASSOCIATED WITH ACCELERATED VASCULAR AGEING: INITIAL RESULTS OF THE UK RESEARCH ALLIANCE INTO KIDNEY DISEASE AND ARTERIAL STIFFNESS (UREKA) COLLABORATION: 8A.02. <i>Journal of Hypertension</i> , 2010, 28, e417.	0.3	3
59	Circulating methylarginine levels and the decline in renal function in patients with chronic kidney disease are modulated by DDAH1 polymorphisms. <i>Kidney International</i> , 2010, 77, 459-467.	2.6	26
60	P9.09 DIFFERENCE IN AGE-RELATED PATTERNS OF ARTERIAL STIFFNESS AND WAVE REFLECTIONS AMONG PATIENTS WITH KIDNEY DISEASE: RESULTS OF THE UK RESEARCH ALLIANCE INTO KIDNEY DISEASE AND ARTERIAL STIFFNESS (UREKA) COLLABORATION. <i>Artery Research</i> , 2010, 4, 174.	0.3	1
61	Prospective Monitoring of Epstein-Barr Virus DNA in Adult Renal Transplant Recipients During the Early Posttransplant Period: Role of Mycophenolate Mofetil. <i>Transplantation</i> , 2009, 87, 852-856.	0.5	24
62	VASCULAR CALCIFICATION IN PATIENTS WITH KIDNEY DISEASE: Arterial Calcification in Dialysis Patients and Transplant Recipients. <i>Seminars in Dialysis</i> , 2007, 20, 144-149.	0.7	15
63	Antiviral treatment after solid organ transplantation. <i>Lancet, The</i> , 2005, 366, 806-807.	6.3	7
64	Dinucleotide repeat polymorphism at the HOX 2B locus. <i>Human Molecular Genetics</i> , 1992, 1, 218-218.	1.4	5